期刊文献+

Progress in target therapy of advanced non-small cell lung cancer

下载PDF
导出
摘要 Lung cancer is one of the most common malignant tumors,and its morbidity and mortality are relatively high.Especially for small cell lung cancer(SCLC),the mortality rate is between 80-90%.Unfortunately,more than 50%of lung cancer patients are diagnosed at an advanced stage.The traditional treatment for advanced non-small cell lung cancer(NSCLC)is chemotherapy.In recent years,with the rapid development of molecular pathology,we have a deeper understanding of the underlying pathological mechanism and heterogeneity of lung cancer,especially NSCLC.Molecular targeted therapy is more accurate because of its anti-tumor effect,and the incidence of adverse drug reactions is low.Compared with chemotherapy in the traditional sense,the degree of damage to normal tissues is also significantly reduced.Therefore,it has become a research hotspot in recent years.This article reviews the research progress of various molecular targeted drugs for the treatment of lung cancer based on domestic and foreign research literature and related data.
作者 Li Zhang Rui Cao
出处 《Drug Combination Therapy》 2021年第4期5-10,共6页 药物联合治疗
  • 相关文献

参考文献1

二级参考文献14

  • 1Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer [ J ]. Semin Oncol, 2006,33 (4): 369-385.
  • 2Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Ireesa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tymsine kinase [J]. Cancer Res, 2002, 62 (9) : 2554-2560.
  • 3Bonomi P. Erlelinib:a new therapeutic, approach for non-small cell lung cancer [J]. Expert Opin Investig Drugs, 2003,12 (8) : 1395-1401.
  • 4Fukuoka M, Yano S, Gisccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib tor previously treated patients with advanced non-small-cell lung cancer [J]. J Clin Oncol, 2003,21 (12) :2237-2246.
  • 5Kris M G, Natale R B, Herbst R S, et al. Effieacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosinc kinase inhibitor, in symptomatic patients with non- small cell lung cancer: a randomized trial [J]. JAMA, 2003, 290(16) :2149-2158.
  • 6Thateher N, Chang A, Parikh P, et al. Gefitinih plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentery study (Iressa Survival Evaluation in Lung Cancer) [J]. Lancet, 2005,366 (9496): 1527-1537.
  • 7Shepherd F A, Rodrigues Pereira J, Ciuleanu T, et al. Edotinib in previously treated non-small-cell lung cancer [J]. N Eng J Med, 2005,353(2) :123-132.
  • 8Lai C S, Boshoff C, Falzon M, et al. Complete tespouse to erlotinib treatment in brain metastases from recurrent NSCLC [J ]. Thorax, 2006,61 ( 1 ) :91.
  • 9Becker A, van Wijk A, Smit E F, et al. Side-effec, ts of long- term administration of erlotinib in patients with non-small cell lung cancer [J]. J Thorac Oncol, 2010,5(9) : 1477-1480.
  • 10Wu J Y, Wu S G, Yang C H, et al. Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations [J ]. Lung Cancer, 2011,72(2) : 205-212.

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部